Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104566 · ClinicalTrials.gov registry record · Phase 3
Global Trial in APG2575 for Patients With CLL/SLL
A Phase 3 study of CLL/SLL, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 2
- Study locations
NCT06104566: Recruiting Phase 3 study of CLL/SLL, sponsored by Ascentage Pharma Group.
NCT06104566 is a Phase 3 study of CLL/SLL that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 400 participants, above the 60-participant average among 6 other CLL/SLL trials with a reported enrollment target (567% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06104566, a Phase 3 study of CLL/SLL, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Primary Outcome
To evaluate the progression-free survival (PFS) of lisaftoclax in combination with BTKi compared with BTKi monotherapy in CLL/SLL patients previously treated with BTKi as determined by independent radiological review committee (IRC) using the iwCLL guidelines
Conditions Studied
Interventions
- DRUG lisaftoclax +BTK inhibitor
- DRUG BTK inhibitor
Study Locations (2)
Texas
- MD Anderson Cancer Center - Houston
Other
- Kaluga Regional Clinical Research - Kaluga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
What NCT06104566 shows while recruiting
NCT06104566 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 6 other CLL/SLL trials with a reported enrollment target (567% higher).
The record links to 1 condition, with CLL/SLL appearing as the primary indexed condition, and to 2 interventions - of which lisaftoclax +BTK inhibitor is the first listed.
NCT06104566 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06104566 about?
NCT06104566 is a clinical study titled "Global Trial in APG2575 for Patients With CLL/SLL". This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
What is the current status of trial NCT06104566?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-12-20. Estimated completion is 2027-10-31.
What conditions does trial NCT06104566 study?
This clinical trial studies the following conditions: CLL/SLL.
What interventions are being tested in trial NCT06104566?
The interventions under investigation include: lisaftoclax +BTK inhibitor (DRUG), BTK inhibitor (DRUG).
Who is sponsoring clinical trial NCT06104566?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104566 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL/SLL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
RECRUITING · Phase 2
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
RECRUITING · Phase 1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RECRUITING · Phase 1
-
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
RECRUITING · Phase 2
-
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
RECRUITING · Phase 1
-
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI